Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus placebo in moderate to severe hidradenitis suppurativa after prior biologic failure or intolerance
NL-OMON58799Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Upadacitinib with Placebo (2 arms). Primary endpoint: HiSCR 50 at Week 16. Started Nov 2023; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON58799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58799.